Logo image of AGEN

AGENUS INC (AGEN) Stock Fundamental Analysis

USA - NASDAQ:AGEN - US00847G8042 - Common Stock

4.34 USD
+0.01 (+0.23%)
Last: 11/14/2025, 8:00:00 PM
4.34 USD
0 (0%)
After Hours: 11/14/2025, 8:00:00 PM
Fundamental Rating

1

AGEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. AGEN has a bad profitability rating. Also its financial health evaluation is rather negative. AGEN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

AGEN had negative earnings in the past year.
AGEN had a negative operating cash flow in the past year.
In the past 5 years AGEN always reported negative net income.
In the past 5 years AGEN reported 4 times negative operating cash flow.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

AGEN has a Return On Assets of -89.45%. This is in the lower half of the industry: AGEN underperforms 72.88% of its industry peers.
Industry RankSector Rank
ROA -89.45%
ROE N/A
ROIC N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

AGEN's Gross Margin of 99.37% is amongst the best of the industry. AGEN outperforms 98.12% of its industry peers.
AGEN's Gross Margin has been stable in the last couple of years.
AGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

0

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGEN has more shares outstanding
Compared to 5 years ago, AGEN has more shares outstanding
Compared to 1 year ago, AGEN has a worse debt to assets ratio.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

AGEN has an Altman-Z score of -19.26. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.
AGEN's Altman-Z score of -19.26 is on the low side compared to the rest of the industry. AGEN is outperformed by 83.62% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.26
ROIC/WACCN/A
WACC8.6%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

2.3 Liquidity

A Current Ratio of 0.06 indicates that AGEN may have some problems paying its short term obligations.
The Current ratio of AGEN (0.06) is worse than 97.74% of its industry peers.
AGEN has a Quick Ratio of 0.06. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
AGEN's Quick ratio of 0.06 is on the low side compared to the rest of the industry. AGEN is outperformed by 97.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

3

3. Growth

3.1 Past

AGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.05%, which is quite impressive.
The Revenue for AGEN has decreased by -33.81% in the past year. This is quite bad
Measured over the past years, AGEN shows a decrease in Revenue. The Revenue has been decreasing by -7.17% on average per year.
EPS 1Y (TTM)81.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
Revenue 1Y (TTM)-33.81%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%20.26%

3.2 Future

The Earnings Per Share is expected to grow by 14.43% on average over the next years. This is quite good.
The Revenue is expected to grow by 15.58% on average over the next years. This is quite good.
EPS Next Y111.27%
EPS Next 2Y36.57%
EPS Next 3Y20.76%
EPS Next 5Y14.43%
Revenue Next Year52.97%
Revenue Next 2Y10.81%
Revenue Next 3Y1.88%
Revenue Next 5Y15.58%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20

1

4. Valuation

4.1 Price/Earnings Ratio

AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

AGEN's earnings are expected to grow with 20.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.57%
EPS Next 3Y20.76%

0

5. Dividend

5.1 Amount

AGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

AGENUS INC

NASDAQ:AGEN (11/14/2025, 8:00:00 PM)

After market: 4.34 0 (0%)

4.34

+0.01 (+0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners29.93%
Inst Owner Change-0.54%
Ins Owners1.71%
Ins Owner Change0.3%
Market Cap138.27M
Revenue(TTM)103.46M
Net Income(TTM)-165.68M
Analysts80
Price Target12.58 (189.86%)
Short Float %6.21%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-66.73%
Min EPS beat(2)-172.44%
Max EPS beat(2)38.98%
EPS beat(4)2
Avg EPS beat(4)-35.41%
Min EPS beat(4)-172.44%
Max EPS beat(4)38.98%
EPS beat(8)4
Avg EPS beat(8)-41.25%
EPS beat(12)6
Avg EPS beat(12)-28.23%
EPS beat(16)9
Avg EPS beat(16)-17.97%
Revenue beat(2)0
Avg Revenue beat(2)-29.94%
Min Revenue beat(2)-49.33%
Max Revenue beat(2)-10.55%
Revenue beat(4)0
Avg Revenue beat(4)-24.86%
Min Revenue beat(4)-49.33%
Max Revenue beat(4)-10.55%
Revenue beat(8)1
Avg Revenue beat(8)-15.24%
Revenue beat(12)4
Avg Revenue beat(12)-4.78%
Revenue beat(16)7
Avg Revenue beat(16)3.5%
PT rev (1m)0%
PT rev (3m)7.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1000%
EPS NY rev (1m)0%
EPS NY rev (3m)142.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)123.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)28.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-4.01
FCFYN/A
OCF(TTM)-4.01
OCFYN/A
SpS3.19
BVpS-11.13
TBVpS-11.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -89.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.37%
FCFM N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
F-Score2
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.66%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -19.26
F-Score2
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)280.5%
Cap/Depr(5y)277.58%
Cap/Sales(3y)20.35%
Cap/Sales(5y)15.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
EPS Next Y111.27%
EPS Next 2Y36.57%
EPS Next 3Y20.76%
EPS Next 5Y14.43%
Revenue 1Y (TTM)-33.81%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%20.26%
Revenue Next Year52.97%
Revenue Next 2Y10.81%
Revenue Next 3Y1.88%
Revenue Next 5Y15.58%
EBIT growth 1Y19.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.17%
EBIT Next 3Y-10.15%
EBIT Next 5Y-10.98%
FCF growth 1Y45.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.49%
OCF growth 3YN/A
OCF growth 5YN/A

AGENUS INC / AGEN FAQ

Can you provide the ChartMill fundamental rating for AGENUS INC?

ChartMill assigns a fundamental rating of 1 / 10 to AGEN.


What is the valuation status for AGEN stock?

ChartMill assigns a valuation rating of 1 / 10 to AGENUS INC (AGEN). This can be considered as Overvalued.


What is the profitability of AGEN stock?

AGENUS INC (AGEN) has a profitability rating of 1 / 10.


Can you provide the financial health for AGEN stock?

The financial health rating of AGENUS INC (AGEN) is 0 / 10.